Paratek Pharmaceuticals News

Date	Title
Aug 29, 2018	Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference
Aug 08, 2018	FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
Aug 08, 2018	Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections
Aug 02, 2018	Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
Jul 23, 2018	Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
Jun 20, 2018	Paratek Announces FDA Advisory Committee Date for Omadacycline
Jun 11, 2018	Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018
Jun 07, 2018	Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018
Jun 01, 2018	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 22, 2018	Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity

APPLY NOW